Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Adnectin-drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors.

Lipovšek D, Carvajal I, Allentoff AJ, Barros A Jr, Brailsford J, Cong Q, Cotter P, Gangwar S, Hollander C, Lafont V, Lau WL, Li W, Moreta M, O'Neil S, Pinckney J, Smith MJ, Su J, Terragni C, Wallace MA, Wang L, Wright M, Marsh HN, Bryson JW.

Protein Eng Des Sel. 2018 May 1;31(5):159-171. doi: 10.1093/protein/gzy013.

2.

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Barjon C, Michaud HA, Fages A, Dejou C, Zampieri A, They L, Gennetier A, Sanchez F, Gros L, Eliaou JF, Bonnefoy N, Lafont V.

Oncoimmunology. 2017 Oct 4;7(1):e1379642. doi: 10.1080/2162402X.2017.1379642. eCollection 2017.

3.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

4.

Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, Kim J, Pena A, Kukral D, Dischino DD, Chow P, Gan J, Adelakun O, Wang XT, Cao K, Leung D, Bonacorsi SJ Jr, Hayes W.

J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.

5.

Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates.

Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, Morin PE, Huang RY, Chow PL, Hayes W, Bonacorsi S Jr.

Bioorg Med Chem. 2017 Oct 15;25(20):5407-5414. doi: 10.1016/j.bmc.2017.07.066. Epub 2017 Aug 4.

PMID:
28803798
6.

Relearning of Activities of Daily Living: A Comparison of the Effectiveness of Three Learning Methods in Patients with Dementia of the Alzheimer Type.

Bourgeois J, Laye M, Lemaire J, Leone E, Deudon A, Darmon N, Giaume C, Lafont V, Brinck-Jensen S, Dechamps A, König A, Robert P.

J Nutr Health Aging. 2016 Jan;20(1):48-55. doi: 10.1007/s12603-015-0597-6.

PMID:
26728933
7.

[Alzheimer's disease and the organization of visits to cultural sites].

Lafont V, Brinck-Jensen S, Filleau C, Greenblat C, David R, Robert P.

Soins Gerontol. 2015 Jul-Aug;(114):39-42. doi: 10.1016/j.sger.2015.03.012. French.

PMID:
26163414
8.

Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L.

Oncoimmunology. 2014 Dec 13;3(9):e955684. eCollection 2014 Oct. Review.

9.

Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay.

Ni YG, Yuan X, Newitt JA, Peterson JE, Gleason CR, Haulenbeek J, Santockyte R, Lafont V, Marsilio F, Neely RJ, DeSilva B, Piccoli SP.

AAPS J. 2015 Jul;17(4):976-87. doi: 10.1208/s12248-015-9762-4. Epub 2015 May 1.

10.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N.

Front Immunol. 2014 Dec 8;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. Review.

11.

Full restoration of Brucella-infected dendritic cell functionality through Vγ9Vδ2 T helper type 1 crosstalk.

Ni M, Martire D, Scotet E, Bonneville M, Sanchez F, Lafont V.

PLoS One. 2012;7(8):e43613. doi: 10.1371/journal.pone.0043613. Epub 2012 Aug 22.

12.

Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.

Bessoles S, Ni M, Garcia-Jimenez S, Sanchez F, Lafont V.

Eur J Immunol. 2011 Jun;41(6):1619-28. doi: 10.1002/eji.201041230. Epub 2011 May 25.

13.

The new species Brucella microti replicates in macrophages and causes death in murine models of infection.

Jiménez de Bagüés MP, Ouahrani-Bettache S, Quintana JF, Mitjana O, Hanna N, Bessoles S, Sanchez F, Scholz HC, Lafont V, Köhler S, Occhialini A.

J Infect Dis. 2010 Jul 1;202(1):3-10. doi: 10.1086/653084.

PMID:
20497040
14.

How much binding affinity can be gained by filling a cavity?

Kawasaki Y, Chufan EE, Lafont V, Hidaka K, Kiso Y, Mario Amzel L, Freire E.

Chem Biol Drug Des. 2010 Feb;75(2):143-51. doi: 10.1111/j.1747-0285.2009.00921.x. Epub 2009 Dec 17.

15.

Differential role of autophagy in CD4 T cells and macrophages during X4 and R5 HIV-1 infection.

Espert L, Varbanov M, Robert-Hebmann V, Sagnier S, Robbins I, Sanchez F, Lafont V, Biard-Piechaczyk M.

PLoS One. 2009 Jun 3;4(6):e5787. doi: 10.1371/journal.pone.0005787.

16.

Human CD4+ invariant NKT cells are involved in antibacterial immunity against Brucella suis through CD1d-dependent but CD4-independent mechanisms.

Bessoles S, Dudal S, Besra GS, Sanchez F, Lafont V.

Eur J Immunol. 2009 Apr;39(4):1025-35. doi: 10.1002/eji.200838929.

17.

The IFNgamma-induced STAT1-CBP/P300 association, required for a normal response to the cytokine, is disrupted in Brucella-infected macrophages.

Bouhet S, Lafont V, Billard E, Gross A, Dornand J.

Microb Pathog. 2009 Feb;46(2):88-97. doi: 10.1016/j.micpath.2008.10.011. Epub 2008 Nov 13.

PMID:
19041714
18.

IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines.

Bessoles S, Fouret F, Dudal S, Besra GS, Sanchez F, Lafont V.

J Leukoc Biol. 2008 Jul;84(1):224-33. doi: 10.1189/jlb.1007669. Epub 2008 May 2.

PMID:
18456817
19.

Identification and isolation of Brucella suis virulence genes involved in resistance to the human innate immune system.

Liautard J, Ouahrani-Bettache S, Jubier-Maurin V, Lafont V, Köhler S, Liautard JP.

Infect Immun. 2007 Nov;75(11):5167-74. Epub 2007 Aug 20.

20.

Compensating enthalpic and entropic changes hinder binding affinity optimization.

Lafont V, Armstrong AA, Ohtaka H, Kiso Y, Mario Amzel L, Freire E.

Chem Biol Drug Des. 2007 Jun;69(6):413-22.

PMID:
17581235
21.
22.

Impairment of TNF-alpha production and action by imidazo[1,2- alpha] quinoxalines, a derivative family which displays potential anti-inflammatory properties.

Morjaria S, Deleuze-Masquefa C, Lafont V, Gayraud S, Bompart J, Bonnet PA, Dornand J.

Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):525-38.

PMID:
17026837
23.

Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against Brucella suis.

Dudal S, Turriere C, Bessoles S, Fontes P, Sanchez F, Liautard J, Liautard JP, Lafont V.

J Immunol. 2006 Oct 15;177(8):5533-9.

24.

Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study.

Dejaegere A, Choulier L, Lafont V, De Genst E, Altschuh D.

Biochemistry. 2005 Nov 8;44(44):14409-18.

PMID:
16262241
25.

Vgamma9Vdelta2 T cells use a combination of mechanisms to limit the spread of the pathogenic bacteria Brucella.

Oliaro J, Dudal S, Liautard J, Andrault JB, Liautard JP, Lafont V.

J Leukoc Biol. 2005 May;77(5):652-60. Epub 2005 Jan 24.

PMID:
15668339
26.

Impairment of intramacrophagic Brucella suis multiplication by human natural killer cells through a contact-dependent mechanism.

Dornand J, Lafont V, Oliaro J, Terraza A, Castaneda-Roldan E, Liautard JP.

Infect Immun. 2004 Apr;72(4):2303-11.

27.

Specific signaling pathways triggered by IL-2 in human V gamma 9V delta 2 T cells: an amalgamation of NK and alpha beta T cell signaling.

Lafont V, Loisel S, Liautard J, Dudal S, Sablé-Teychené M, Liautard JP, Favero J.

J Immunol. 2003 Nov 15;171(10):5225-32.

28.

The innate immune response against Brucella in humans.

Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP.

Vet Microbiol. 2002 Dec 20;90(1-4):383-94. Review.

PMID:
12414158
29.

Functional aspects of co-variant surface charges in an antibody fragment.

Hugo N, Lafont V, Beukes M, Altschuh D.

Protein Sci. 2002 Nov;11(11):2697-705.

31.
32.

Evaluation of the supervisory system in elderly subjects with and without disinhibition.

Gokalsing E, Robert PH, Lafont V, Medecin I, Baudu C, Boyer P, Pringuey D, Darcourt G.

Eur Psychiatry. 2000 Nov;15(7):407-15.

PMID:
11112933
33.
34.

Covariance analysis of protein families: the case of the variable domains of antibodies.

Choulier L, Lafont V, Hugo N, Altschuh D.

Proteins. 2000 Dec 1;41(4):475-84.

PMID:
11056035
35.
36.

Tumor necrosis factor-alpha production is differently regulated in gamma delta and alpha beta human T lymphocytes.

Lafont V, Liautard J, Gross A, Liautard JP, Favero J.

J Biol Chem. 2000 Jun 23;275(25):19282-7.

37.

[Diagnostic criteria for fronto-temporal lobe degeneration].

Robert PH, Lafont V, Snowden JS, Lebert F.

Encephale. 1999 Nov-Dec;25(6):612-21. French.

PMID:
10668605
38.
39.

Clustering and switching strategies in verbal fluency tasks: comparison between schizophrenics and healthy adults.

Robert PH, Lafont V, Medecin I, Berthet L, Thauby S, Baudu C, Darcourt G.

J Int Neuropsychol Soc. 1998 Nov;4(6):539-46.

PMID:
10050358
40.

Effector pathways regulating T cell activation.

Favero J, Lafont V.

Biochem Pharmacol. 1998 Dec 15;56(12):1539-47. Review.

PMID:
9973174
41.

Initiation and supervisory processes in schizophrenia and depression.

Lafont V, Medecin I, Robert PH, Beaulieu FE, Kazes M, Danion JM, Pringuey D, Darcourt G.

Schizophr Res. 1998 Nov 9;34(1-2):49-57.

PMID:
9824876
43.

Transferrin receptor functions as a signal-transduction molecule for its own recycling via increases in the internal Ca2+ concentration.

Sainte-Marie J, Lafont V, Pécheur EI, Favero J, Philippot JR, Bienvenüe A.

Eur J Biochem. 1997 Dec 15;250(3):689-97.

44.

Inhibition of HIV Infection by Lectin Binding to CD4.

Favero J, Lafont V.

Methods Mol Med. 1998;9:539-53. doi: 10.1385/0-89603-396-1:539.

PMID:
21374491
45.

Interaction of Yersinia enterocolitica with macrophages leads to macrophage cell death through apoptosis.

Ruckdeschel K, Roggenkamp A, Lafont V, Mangeat P, Heesemann J, Rouot B.

Infect Immun. 1997 Nov;65(11):4813-21.

46.

The lectin jacalin specifically triggers cell signaling in CD4+ T lymphocytes.

Lafont V, Hivroz C, Carayon P, Dornand J, Favero J.

Cell Immunol. 1997 Oct 10;181(1):23-9.

PMID:
9344492
47.

Evidence for a CD4-associated calcium influx independent of the phosphoinositide transduction pathway in human T cells.

Lafont V, Fischer T, Zumbihl R, Faure S, Hivroz C, Rouot B, Favero J.

Eur J Immunol. 1997 Sep;27(9):2261-8.

PMID:
9341768
49.

The lectin jacalin triggers CD4-mediated lymphocyte signaling by binding CD4 through a protein-protein interaction.

Lafont V, Dornand J, Covassin L, Liautard JP, Favero J.

J Leukoc Biol. 1996 May;59(5):691-6.

PMID:
8656054
50.

Jacalin, a lectin that inhibits in vitro HIV-1 infection, induces intracellular calcium increase via CD4 in cells lacking the CD3/TcR complex.

Lafont V, Dornand J, d'Angeac AD, Monier S, Alcover A, Favero J.

J Leukoc Biol. 1994 Oct;56(4):521-4.

PMID:
7930950

Supplemental Content

Loading ...
Support Center